$1.85
+0.04 (+2.21%)
Open$1.81
Previous Close$1.81
Day High$1.88
Day Low$1.80
52W High$19.40
52W Low$1.31
Volume—
Avg Volume3.01M
Market Cap68.11M
P/E Ratio—
EPS$-1.47
SectorBiotechnology
Analyst Ratings
Buy
16 analysts
Price Target
+1,701.6% upside
Current
$1.85
$1.85
Target
$33.33
$33.33
$30.09
$33.33 avg
$42.13
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 19.99M | 20.76M | 15.61M |
| Net Income | 4.98M | 4.98M | 3.68M |
| Profit Margin | 24.9% | 24.0% | 23.6% |
| EBITDA | 7.23M | 8.32M | 5.37M |
| Free Cash Flow | 5.95M | 3.82M | 3.47M |
| Rev Growth | +24.3% | +21.0% | +20.1% |
| Debt/Equity | 0.81 | 0.72 | 0.85 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |